Egypt Mouth Ulcer Therapeutics Market Analysis

Egypt Mouth Ulcer Therapeutics Market Executive Summary

The Egypt Mouth Ulcer Therapeutics Market is at around $4.3 Mn in 2023 and is projected to reach $6.2 Mn in 2030, exhibiting a CAGR of 5.4% during the forecast period 2023-2030.

Mouth ulcers, also known as canker sores, are classified into three main types: minor aphthous ulcers which are the most common small oval lesions, major aphthous ulcers that are larger and deeper causing more pain, and herpetiform ulcers which start as multiple small ulcers that can merge into one large ulcer. While the exact cause is unknown, several risk factors have been identified including stress, anxiety, hormonal changes, nutritional deficiencies (iron, vitamin B12, folic acid, zinc), certain medical conditions like celiac disease, Crohn's disease, and HIV/AIDS, as well as trauma from dental work, braces, or ill-fitting dentures. In most cases, mouth ulcers are self-limiting and resolve within 1-2 weeks without treatment. However, complications can arise such as secondary infection, severe pain affecting one's ability to eat or drink properly, and potential scarring in cases of severe recurrent ulcers. Prevention involves reducing stress, avoiding potential food triggers like citrus fruits, nuts, and chips, using soft-bristled toothbrushes and waxed dental floss, and replacing toothpaste if it seems to be a trigger. Treatment involves symptomatic relief with topical gels containing anaesthetics, antiseptics, and antibiotics, as well as supportive care with multivitamins or vitamin supplements, antipyretics, and antibiotics. Medications include antibiotics, oral painkillers, oral steroids, antiseptics, chlorhexidine gluconate mouthwash, and sucralfate. Home care includes good oral hygiene, avoiding trigger foods, warm saline gargles, ice packs, and a balanced diet. Medical attention is necessary if the ulcers fail to heal within a week or two, are unusual, spreading, or large, or if there is severe pain, fever, or difficulty while chewing, talking, or swallowing.

The market therefore is driven by significant factors like advancements in healthcare, lifestyle changes and increasing prevalence, however, factors such as limited accessibility, and reliance on traditional remedies limit market growth.

The industry is primarily dominated by players such as EIPICO, Pharco Pharmaceuticals, Amoun Pharmaceuticals, GlaxoSmithKline PLC, Rameda Pharmaceuticals, Takeda, Teva Pharmaceuticals among others.

Market Dynamics

Market Growth Drivers

Unhealthy Lifestyles: The growing prevalence of unhealthy lifestyles, such as poor diet and lack of exercise, is also contributing to the rise in mouth ulcers. These factors can weaken the immune system, making individuals more susceptible to mouth ulcers. The increasing prevalence of stress and anxiety in modern life is another factor contributing to the rise in mouth ulcers. Stress can weaken the immune system, making individuals more prone to mouth ulcers.

Advancements in Healthcare: The development of new and innovative treatments for mouth ulcers, such as rapidly healing gels and flavoured mouthwashes, is enhancing the market growth. These products offer more effective and convenient treatment options for individuals with mouth ulcers.

Increasing Prevalence: The prevalence of aphthous ulcers in Egypt ranges from 2% to 66% in different populations. The rise in the prevalence of mouth ulcers due to various factors, such as tobacco consumption, unhealthy lifestyles, and stress, contributes to market growth. As the number of individuals affected by mouth ulcers increases, the demand for effective treatment options also rises.

Market Restraints

Competition from Home Remedies: The availability of home remedies and over-the-counter medications provides more affordable alternatives to pharmaceutical treatments for mouth ulcers. These alternatives can be appealing to individuals with limited financial resources or those seeking more natural approaches. The competition from these alternatives constrains the growth of the pharmaceutical mouth ulcer treatment market.

Limited Accessibility to Pharmaceuticals: In some areas of Egypt, access to pharmaceutical treatments for mouth ulcers may be limited due to cost or availability issues. This limited accessibility can hinder market growth and limit the reach of effective pharmaceutical treatments.

Regulatory Landscape and Reimbursement Scenario

The regulatory body responsible for the pharmaceutical industry in Egypt is the Egyptian Drug Authority (EDA). The EDA is responsible for ensuring the safety and efficacy of drugs and medical devices in the country. The EDA is also responsible for the registration and marketing authorization of pharmaceutical products, as well as the monitoring of their quality and safety.

The reimbursement system in Egypt is managed by the Health Insurance Organization (HIO) and the Universal Health Insurance Authority (UHIA). The HIO formulary lists medications by their International Non-proprietary Names (INNs) and does not have any reimbursement criteria. The UHIA formulary lists medications by their INNs and brand names and includes a Health Technology Assessment (HTA) process for innovative medicines. In the UHIA formulary, generics with the least price are fully reimbursed, while higher-price generics and brands are partially reimbursed, and patients pay a co-payment.

The EDA plays a crucial role in controlling hepatitis in Egypt by ensuring that all pharmaceutical products, including those for hepatitis treatment, meet the necessary safety and efficacy standards. The EDA also monitors the quality and safety of these products and takes action against any products that do not meet these standards.

Competitive Landscape

Key Players

Here are some of the major key players in the Egypt Mouth Ulcers Therapeutics Market:

• EIPICO
• Pharco Pharmaceuticals
• Amoun Pharmaceuticals
• EVA Pharma
• Rameda Pharmaceuticals
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Novartis
• Sanofi
• Takeda

Teva Pharmaceuticals